Programming Grants to Accompany NEH on the Road Exhibitions
Deadline : 1-7-2019
Funding Opportunity : PA-16-072
CFDA : 93.273|93.279|000000
Agency : Department of Health and Human Services
Contact : NIH OER Webmaster
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Eligibility : State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Native American Tribal Governments (Federally recognized)
Public Housing Authorities/Indian Housing Authorities
Native American Tribal Organizations (other than Federally recognized tribal governments)
Nonprofits Having a 501 (c) (3) Status with the IRS (other than institutions of higher education)
Nonprofits that do not have a 501 (c) (3) status with the IRS (other than institutions of higher education)
Private institutions of higher education
For-profit organizations other than small business
Small businesses
Others
Details :
The purpose of this FOA is to encourage behavioral intervention development research to test efficacy, conduct clinical trials, examine mechanisms of behavior change, determine dose-response, optimize combinations, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological (1) drug abuse treatment interventions, including interventions for patients with comorbidities, in diverse settings; (2) drug abuse treatment and adherence interventions for use in primary care; (3) drug abuse treatment and adherence interventions that utilize technologies to boost effects and increase implementability; (4) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (5) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (6) interventions to treat chronic pain. Research of interest includes but is not limited to Stage II and Stage III efficacy research.
